RUNX2-modifying enzymes: therapeutic targets for bone diseases

被引:64
作者
Kim, Woo-Jin [1 ]
Shin, Hye-Lim [1 ]
Kim, Bong-Soo [1 ]
Kim, Hyun-Jung [1 ]
Ryoo, Hyun-Mo [1 ]
机构
[1] Seoul Natl Univ, Basic Res Lab Epigenet Regenerat Aged Skeletomusc, Dept Mol Genet & Dent Pharmacol, Sch Dent,Dent Res Inst, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
FIBROBLAST-GROWTH-FACTOR; PROLYL-ISOMERASE PIN1; OSTEOBLAST DIFFERENTIATION; SIGNALING PATHWAYS; RUNX2; EXPRESSION; PREVENTS; PHOSPHORYLATION; INHIBITOR; FGFR2;
D O I
10.1038/s12276-020-0471-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RUNX2 is a master transcription factor of osteoblast differentiation. RUNX2 expression in the bone and osteogenic front of a suture is crucial for cranial suture closure and membranous bone morphogenesis. In this manner, the regulation of RUNX2 is precisely controlled by multiple posttranslational modifications (PTMs) mediated by the stepwise recruitment of multiple enzymes. Genetic defects inRUNX2itself or in its PTM regulatory pathways result in craniofacial malformations. Haploinsufficiency in RUNX2 causes cleidocranial dysplasia (CCD), which is characterized by open fontanelle and hypoplastic clavicles. In contrast, gain-of-function mutations in FGFRs, which are known upstream stimulating signals of RUNX2 activity, cause craniosynostosis (CS) characterized by premature suture obliteration. The identification of these PTM cascades could suggest suitable drug targets for RUNX2 regulation. In this review, we will focus on the mechanism of RUNX2 regulation mediated by PTMs, such as phosphorylation, prolyl isomerization, acetylation, and ubiquitination, and we will summarize the therapeutics associated with each PTM enzyme for the treatment of congenital cranial suture anomalies. Regenerative medicine: Manipulating modifications that control bone-building Therapies that modulate the activity of the regulatory protein RUNX2 could potentially restore normal bone development in a range of skeletal disorders, and repair damage from injury or degeneration. RUNX2 is an essential regulator of genes that drive formation of bone-producing osteoblast cells. It can be activated or inactivated by the enzymatic addition of various chemical groups. Hyun-Mo Ryoo and colleagues at Seoul National University, South Korea, review the role of such modifications in bone disorders. For example, the loss of modifications activated by RUNX2 can result in delayed integration of the bones that form the skull. The authors highlight potential opportunities to manipulate these modification processes to treat this and other developmental disorders. Similar strategies could also promote repair of fractures or counter osteoporotic bone loss.
引用
收藏
页码:1178 / 1184
页数:7
相关论文
共 50 条
[41]   RUNX Family as a Promising Biomarker and a Therapeutic Target in Bone Cancers: A Review on Its Molecular Mechanism(s) behind Tumorigenesis [J].
Vimalraj, Selvaraj ;
Sekaran, Saravanan .
CANCERS, 2023, 15 (12)
[42]   Bone development by Hedgehog and Wnt signaling, Runx2, and Sp7 [J].
Komori, Toshihisa .
JOURNAL OF BONE AND MINERAL METABOLISM, 2025, 43 (01) :33-38
[43]   Runx2 overexpression promotes bone repair of osteonecrosis of the femoral head (ONFH) [J].
Xu, Hai-Jia ;
Liu, Xiang-Zhong ;
Yang, Lu ;
Ning, Yu ;
Xu, Liang-Liang ;
Sun, Da-Ming ;
Liao, Wen ;
Yang, Yi ;
Li, Zhang-Hua .
MOLECULAR BIOLOGY REPORTS, 2023, 50 (06) :4769-4779
[44]   Integrin and cadherin signaling in bone: role and potential therapeutic targets [J].
Marie, Pierre J. ;
Hay, Eric ;
Saidak, Zuzana .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2014, 25 (11) :567-575
[45]   Runx2 induces bone osteolysis by transcriptional suppression of TSSC1 [J].
Wang, Da-Chuan ;
Wang, Hai-Feng ;
Yuan, Ze-Nong .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 438 (04) :635-639
[46]   Signaling Dynamics in Osteogenesis: Unraveling Therapeutic Targets for Bone Generation [J].
Yang, Xue D. ;
Haga, Christopher L. ;
Phinney, Donald G. .
CURRENT DRUG TARGETS, 2025, 26 (05) :350-366
[47]   Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis [J].
Baniwal, Sanjeev K. ;
Khalid, Omar ;
Gabet, Yankel ;
Shah, Ruchir R. ;
Purcell, Daniel J. ;
Mav, Deepak ;
Kohn-Gabet, Alice E. ;
Shi, Yunfan ;
Coetzee, Gerhard A. ;
Frenkel, Baruch .
MOLECULAR CANCER, 2010, 9
[48]   RUNX2 as a promising therapeutic target for malignant tumors [J].
Zhao, Weizhu ;
Yang, Haiying ;
Chai, Jie ;
Xing, Ligang .
CANCER MANAGEMENT AND RESEARCH, 2021, 13 :2539-2548
[49]   The Emerging Role of MicroRNAs in Bone Diseases and Their Therapeutic Potential [J].
Bravo Vazquez, Luis Alberto ;
Moreno Becerril, Mariana Yunuen ;
Mora Hernandez, Erick Octavio ;
Leon Carmona, Gabriela Garcia de ;
Aguirre Padilla, Maria Emilia ;
Chakraborty, Samik ;
Bandyopadhyay, Anindya ;
Paul, Sujay .
MOLECULES, 2022, 27 (01)
[50]   GSDMD-mediated pyroptosis: molecular mechanisms, diseases and therapeutic targets [J].
Li, Yujuan ;
Guo, Bin .
MOLECULAR BIOMEDICINE, 2025, 6 (01)